High-risk human papillomavirus in Galicia, Spain: prevalence and evaluation of the sample representativeness

Trigo, Matilde; García-Campello, Marta; Pérez-Ríos, Mónica; Santiago-Pérez, María Isolina; Fernández-Rodríguez, E.; Guinarte, Genoveva; Troncoso, Ana M.; Pardavila, R.; Malvar, Alberto

doi:10.3109/00365548.2014.930966

Cited by 7 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… a Classification of human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [ 25 – 27 ] b Histological classification Bethesda 2001 System [ 24 ] c Negative for intraepithelial lesion or malignancy …”

Section: Resultsmentioning

confidence: 99%

“…HPV types were classified according to the World Health Organization (WHO) International Agency for Research on Cancer (IARC) Monographs Working Group assessment of the carcinogenicity of different HPV types [ 24 – 26 ]: 13 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and 5 likely high-risk (53, 66, 70, 73 MM9, and 82 MM4). The finding of two or more high-risk genotypes in the same patient was defined as co-infection [ 27 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

et al. 2018

View full text Add to dashboard Cite

BackgroundThe new nine-valent vaccine against human papillomavirus (HPV) includes the four HPV genotypes (6, 11, 16, and 18) that are targeted by the older quadrivalent HPV vaccine, plus five additional oncogenic types (31, 33, 45, 52, and 58) remain significantly associated with high grade lesions. We aimed to determine the prevalence of high-risk HPV genotypes in unvaccinated subjects and the association of these genotypes with the incidence of high-grade lesions. We also assessed which, if either, of these two HPV vaccines could have prevented these cases.MethodsThis cross-sectional study, conducted from 4 January 2010 to 30 December 2011, was composed of 595 women attending the Hospital General Universitario de Elche (Spain) gynaecology department who were positively screened for opportunistic cervical cancer by pap smears and HPV detection during a routine gynaecological health check. The pap smear results were classified using the Bethesda system. HPV genotyping was performed with the Linear Array HPV genotyping test, and viruses were classified by the International Agency for Research on Cancer assessment of HPV carcinogenicity. Odds ratios (ORs) with their 95% confidence intervals (95% CI) were estimated by logistic regression, adjusting for age and immigrant status. The prevented fraction among those exposed (PFe-adjusted) was determined as a measure of impact.ResultsAt least one of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine was detected in 20.5% of subjects. After excluding women with genotype 16 and/or 18 co-infection, high-risk genotypes (31, 33, 45, 52, and 58) were associated with a higher risk of intraepithelial lesion or malignancy: adjusted OR = 3.51 (95% CI, 1.29–9.56), PFe-adjusted = 0.72 (95% CI, 0.22–0.90). Genotypes that are still non-vaccine-targeted were detected in 17.98% of the women, but these were not significantly associated with high-grade lesions.ConclusionThe greater protection of the nine-valent HPV vaccine is likely to have a positive impact because, in the absence of genotype 16 or 18 infection, these five genotypes on their own remained significantly associated with high-grade lesions.Electronic supplementary materialThe online version of this article (10.1186/s12885-018-4033-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

et al. 2018

View full text Add to dashboard Cite

show abstract

“…As evidenced by the respondents in this study, remote research visits may increase the ability and willingness of individuals to participate in research, as well as include groups that are generally less likely to participate in PD trials, such as individuals without a PD specialist or women. The National Institute of Neurological Disorders and Stroke also recognizes this potential and called for new means to assess and engage research participants, including investigating “telemedicine to capture long-term outcomes in clinical research cohorts,” in its 2014 PD Research Recommendations [ 36 ]. Another key advantage of remote assessments is the ability to conduct such assessments from a single “center,” which obviates the need for multi-center studies.…”

Section: Discussionmentioning

confidence: 99%

Feasibility of Virtual Research Visits in Fox Trial Finder

Dorsey

Wagner

Bull

et al. 2015

JPD

View full text Add to dashboard Cite

Background: Fox Trial Finder is an online registry for individuals with and without Parkinson disease (PD) interested in participating in PD research. However, distance or disability could prevent such individuals from participating in traditional, clinic-based research at major centers. Objective: Use videoconferencing to connect participants to specialists to: (1) demonstrate feasibility of virtual research visits within this population (2) collect phenotypic data of the participants, (3) validate self-reported diagnosis, and (4) gauge interest in virtual research visits. Methods: We solicited volunteers throughout the United States through Fox Trial Finder. Interested individuals with PD provided consent, were given web cameras if needed, completed baseline surveys, and downloaded videoconferencing software remotely. Participants had a test connection and assessment appointment which included the Montreal Cognitive Assessment (MoCA), then a virtual research visit with a neurologist who reviewed their history and assessed their PD using a modified Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Neurologists assessed PD diagnosis and symptomatology. Physicians and participants were surveyed about their experience. Results: Of 204 individuals who consented, 166 (81% ) individuals from 39 states completed all visits. The mean age was 62 and mean disease duration was 8.0 years. Mean MoCA score was 26.5, and mean modified MDS-UPDRS motor score was 22.8 (out of a possible 124). Neurologists judged PD as the most likely diagnosis in 97% of cases. Overall satisfaction with the visits was 79% (satisfied or very satisfied) among neurologists and 93% among participants. Conclusions: Through virtual research visits, neurologists engaged, characterized, and validated self-reported diagnosis in individuals with PD over a broad geography. This model may facilitate future research participation.

show abstract

“…All samples were tested for the presence of HPV DNA using the LINEAR ARRAY HPV genotyping test (Roche Molecular Diagnostics) protocol, which is capable of genotyping HPV 6,11,16,18,26,31,33,35,39,40,42,45,51,52,53,54,55,56,58,59,61,62,64,66 (16,18,31,33,35,39,45,51,52,56,58,59, and 68) and 5 as probable high risk (53,66,70, 73 MM9, and 82 MM4). The presence of two or more genotypes (high-risk, likely high-risk HPV or low-risk genotypes) in the same woman was defined as multiple infection (49).…”

Section: Samplesmentioning

confidence: 99%

“…The presence of two or more genotypes (high-risk, likely high-risk HPV or low-risk genotypes) in the same woman was defined as multiple infection (49). The presence of two or more high-risk genotypes in the same patient was defined as coinfection (55).…”

Section: Samplesmentioning

confidence: 99%

Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions

Álvarez-Paredes¹,

Santibáñez

Galiana

et al. 2019

Cancer Prevention Research

View full text Add to dashboard Cite

Human papillomavirus genotype 16 (HPV16) is by far the genotype most strongly associated with cervical cancer; viral variant and/or viral load of HPV16 could modulate this association. The objective was to determine the association between the viral variant and viral load of HPV16 and the presence of cervical high-grade lesions. This cross-sectional study included all women in whom HPV infection was found by cervical smear during routine gynecologic health checks. Women with single or multiple HPV16 infections (n ¼ 176) were selected for viral variant and viral load analysis. Smear results were classified using the Bethesda system. HPV types were classified according to the International Agency for Research on Cancer. Odds ratios (OR) with their 95% confidence intervals (CI) were estimated by logistic regression, adjusted for age, immigrant status, and coinfection with other high-risk genotypes. No statistically significant associations were found regarding the detected viral variants. A viral load above the median (>1,367.79 copies/cell) was associated with a significant risk of high-grade epithelial lesion or carcinoma, after adjusting for age, immigrant status, coinfections, and viral variant: (adjusted OR 7.89; 95% CI: 2.75-22.68). This relationship showed a statistically significant dose-response pattern after categorizing by viral load tertiles: adjusted OR for a viral load greater than the third tertile was 17.23 (95% CI: 4.20-70.65), with adjusted linear P trend ¼ 0.001. In patients infected with HPV16, viral load is associated with high-grade intraepithelial lesions or cervical carcinoma. This could be useful as prognostic biomarker of neoplastic progression and as screening for cervical cancer.

show abstract

High-risk human papillomavirus in Galicia, Spain: prevalence and evaluation of the sample representativeness

Abstract: In Galicia in 2009 there would be 96 400 women aged 16-64 years infected with HR-HPV. It is possible to estimate HR-HPV prevalence in a population starting from a volunteer sample.

Cited by 7 publications

References 30 publications

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions

Feasibility of Virtual Research Visits in Fox Trial Finder

Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions

Contact Info

Product

Resources

About